At present, five trials are investigating the use of HDAC inhibitor valproic acid (VPA) in Kaposi sarcoma, EBV-related nasopharyngeal carcinoma and non-Hodgkin's lymphoma, as well as in HIV-infected patients (http://clinicaltrials.gov/). This evidence concerns the gene HDAC9 and nasopharyngeal carcinoma.